Development of a dry powder for inhalation of nanoparticles codelivering cisplatin andABCC3siRNA in lung cancer / Vivek Patel, Denish Bardoliwala, Rohan Lalani, Sushilkumar Patil, Saikat Ghosh, Ankit Javia, Ambikanandan Misra
Background:The current study sought to formulate a dry powder inhalant (DPI) for pulmonary delivery of lipopolymeric nanoparticles (LPNs) consisting of cisplatin and siRNA for multidrug-resistant lung cancer. siRNA against ABCC3 gene was used to silence drug efflux promoter.Results & discussion:The formulation was optimized through the quality by design system by nanoparticle size and cisplatin entrapment. The lipid concentration, polymer concentration and lipid molar ratio were selected as variables. The DPI was characterized byin vitrodeposition study using the Anderson cascade impactor. DPI formulation showed improved pulmonary pharmacokinetic parameters of cisplatin with higher residence time in lungs.Conclusion:Local delivery of siRNA and cisplatin to the lung tissue resulted into an enhanced therapeutic effectiveness in combating drug resistance. Background: Results & discussion: in vitro Conclusion: Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Vivek [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Chemosensitization |
|---|
| Umfang: |
1 Online-Ressource (20 p) |
|---|
| doi: |
10.4155/tde-2020-0117 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011092424 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011092424 | ||
| 003 | DE-627 | ||
| 005 | 20230713210628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2020-0117 |2 doi | |
| 035 | |a (DE-627)KFL011092424 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2020-0117 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Patel, Vivek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of a dry powder for inhalation of nanoparticles codelivering cisplatin andABCC3siRNA in lung cancer |c Vivek Patel, Denish Bardoliwala, Rohan Lalani, Sushilkumar Patil, Saikat Ghosh, Ankit Javia, Ambikanandan Misra |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (20 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background:The current study sought to formulate a dry powder inhalant (DPI) for pulmonary delivery of lipopolymeric nanoparticles (LPNs) consisting of cisplatin and siRNA for multidrug-resistant lung cancer. siRNA against ABCC3 gene was used to silence drug efflux promoter.Results & discussion:The formulation was optimized through the quality by design system by nanoparticle size and cisplatin entrapment. The lipid concentration, polymer concentration and lipid molar ratio were selected as variables. The DPI was characterized byin vitrodeposition study using the Anderson cascade impactor. DPI formulation showed improved pulmonary pharmacokinetic parameters of cisplatin with higher residence time in lungs.Conclusion:Local delivery of siRNA and cisplatin to the lung tissue resulted into an enhanced therapeutic effectiveness in combating drug resistance. Background: Results & discussion: in vitro Conclusion: Graphical abstract | ||
| 653 | |a chemosensitization | ||
| 653 | |a cisplatin | ||
| 653 | |a Cryo-TEM | ||
| 653 | |a DPI | ||
| 653 | |a gene knockdown | ||
| 653 | |a lung cancer | ||
| 653 | |a MTT assay | ||
| 653 | |a PEG-PLA | ||
| 653 | |a RT-PCR | ||
| 653 | |a siRNA | ||
| 700 | 1 | |a Bardoliwala, Denish |e verfasserin |4 aut | |
| 700 | 1 | |a Lalani, Rohan |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Sushilkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Saikat |e verfasserin |4 aut | |
| 700 | 1 | |a Javia, Ankit |e verfasserin |4 aut | |
| 700 | 1 | |a Misra, Ambikanandan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2020-0117 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||